Glial Fibrillary Acidic Protein (GFAP), an emerging fluid biomarker in brain disorders [70] usually employed to identify astrocytic reactivity state, a well-documented process in AD and neurodegeneration, was identified. This evidence concerns the gene GFAP and Alzheimer disease.